{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:39:15Z","timestamp":1787647155364,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T00:00:00Z","timestamp":1724544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T00:00:00Z","timestamp":1724544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00228-024-03740-3","type":"journal-article","created":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T16:10:10Z","timestamp":1724602210000},"page":"1807-1817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of pharmacokinetic target attainment and hematological toxicity of linezolid in pediatric patients"],"prefix":"10.1007","volume":"80","author":[{"given":"Manal","family":"Abouelkheir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maram R.","family":"Aldawsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Ghonem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliyah","family":"Almomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Alsarhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alsubaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyad","family":"Kurdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alsultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,25]]},"reference":[{"issue":"Suppl 1","key":"3740_CR1","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","volume":"59","author":"DC Vinh","year":"2009","unstructured":"Vinh DC, Rubinstein E (2009) Linezolid: a review of safety and tolerability. J Infect 59(Suppl 1):S59-74","journal-title":"J Infect"},{"issue":"3","key":"3740_CR2","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/j.1875-9114.1998.tb03109.x","volume":"18","author":"LD Dresser","year":"1998","unstructured":"Dresser LD, Rybak MJ (1998) The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18(3):456\u2013462","journal-title":"Pharmacotherapy"},{"key":"3740_CR3","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","volume":"42","author":"DJ Stalker","year":"2003","unstructured":"Stalker DJ, Jungbluth GL (2003) Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42:1129\u20131140","journal-title":"Clin Pharmacokinet"},{"key":"3740_CR4","unstructured":"World Health Organization (2022) Antimicrobial resistance. Global antimicrobial resistance and use surveillance system (GLASS) report. WHO. Available from: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/antimicrobial-resistance. Accessed 17 Mar 2024"},{"issue":"4","key":"3740_CR5","doi-asserted-by":"publisher","first-page":"102001","DOI":"10.1016\/j.jsps.2024.102001","volume":"32","author":"H Almutairi","year":"2024","unstructured":"Almutairi H, Albahadel H, Alhifany A et al (2024) Prevalence and antimicrobial susceptibility pattern of methicillin-resistant Staphylococcus aureus (MRSA) at a maternity and children hospital in Saudi Arabia: A cross-sectional study. Saudi Pharm J 32(4):102001","journal-title":"Saudi Pharm J"},{"issue":"9","key":"3740_CR6","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/pathogens12091075","volume":"12","author":"SS Banawas","year":"2023","unstructured":"Banawas SS, Alobaidi AS, Dawoud TM et al (2023) Prevalence of multidrug-resistant bacteria in healthcare-associated bloodstream infections at hospitals in Riyadh, Saudi Arabia. Pathogens 12(9):1075","journal-title":"Pathogens"},{"key":"3740_CR7","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.2147\/IDR.S416020","volume":"16","author":"P Fang","year":"2023","unstructured":"Fang P, Gao K, Yang J et al (2023) Prevalence of multidrug-resistant pathogens causing neonatal early and late onset sepsis, a retrospective study from the tertiary referral children\u2019s hospital. Infect Drug Resist 16:4213\u20134225","journal-title":"Infect Drug Resist"},{"issue":"2","key":"3740_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/antibiotics11020284","volume":"11","author":"M Mariani","year":"2022","unstructured":"Mariani M, Parodi A, Minghetti D et al (2022) Early and late onset neonatal sepsis: epidemiology and effectiveness of empirical antibacterial therapy in a III level neonatal intensive care unit. Antibiotics (Basel) 11(2):284","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"3740_CR9","doi-asserted-by":"publisher","first-page":"12689","DOI":"10.1038\/s41598-020-69058-z","volume":"10","author":"A Shariati","year":"2020","unstructured":"Shariati A, Dadashi M, Moghadam MT et al (2020) Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis. Sci Rep 10(1):12689","journal-title":"Sci Rep"},{"issue":"1","key":"3740_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13756-023-01291-3","volume":"12","author":"MA Belete","year":"2023","unstructured":"Belete MA, Gedefie A, Alemayehu E et al (2023) The prevalence of vancomycin-resistant Staphylococcus aureus in Ethiopia: a systematic review and meta-analysis. Antimicrob Resist Infect Control 12(1):86","journal-title":"Antimicrob Resist Infect Control"},{"issue":"6","key":"3740_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40262-022-01125-2","volume":"61","author":"E Band\u00edn-Vilar","year":"2022","unstructured":"Band\u00edn-Vilar E, Garc\u00eda-Quintanilla L, Castro-Balado A et al (2022) Review of population pharmacokinetic analyses of linezolid. Clin Pharmacokinet 61(6):789\u2013817","journal-title":"Clin Pharmacokinet"},{"key":"3740_CR12","unstructured":"Linezolid. In: Lexicomp Online (2023) Pediatric & Neonatal Lexi-Drugs. Hudson, OH: Lexi-Comp, Inc. Available from: www.online.lexi.com. Accessed 15 Jan 2023"},{"issue":"1","key":"3740_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13756-020-00818-2","volume":"9","author":"L Matrat","year":"2020","unstructured":"Matrat L, Plaisant F, Barreto C et al (2020) Increasing use of linezolid in a tertiary NICU during a 10-year period: reasons and concerns for the future. Antimicrob Resist Infect Control 9(1):156","journal-title":"Antimicrob Resist Infect Control"},{"key":"3740_CR14","doi-asserted-by":"publisher","first-page":"e0139097","DOI":"10.1371\/journal.pone.0139097","volume":"10","author":"E Buccellato","year":"2015","unstructured":"Buccellato E, Melis M, Biagi C et al (2015) Use of antibiotics in pediatrics: 8-year survey in Italian hospitals. PLoS ONE 10:e0139097","journal-title":"PLoS ONE"},{"key":"3740_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/INF.0000000000001769","volume":"37","author":"B Bagga","year":"2018","unstructured":"Bagga B, Buckingham S, Arnold S et al (2018) Increasing linezolid-resistant enterococcus in a children\u2019s hospital. Pediatr Infect Dis J 37:242\u2013244","journal-title":"Pediatr Infect Dis J"},{"key":"3740_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/BCR.0b013e3181c89ee3","volume":"31","author":"MJ Hallam","year":"2010","unstructured":"Hallam MJ, Allen JM, James SE et al (2010) Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis. J Burn Care Res 31:207\u2013209","journal-title":"J Burn Care Res"},{"issue":"8","key":"3740_CR17","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00228-022-03340-z","volume":"78","author":"RM El-Gaml","year":"2022","unstructured":"El-Gaml RM, El-Khodary NM, Abozahra RR et al (2022) Applying pharmacokinetic\/pharmacodynamic measurements for linezolid in critically ill patients: optimizing efficacy and reducing resistance occurrence. Eur J Clin Pharmacol 78(8):1301\u20131310","journal-title":"Eur J Clin Pharmacol"},{"key":"3740_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijantimicag.2011.05.007","volume":"38","author":"H Dong","year":"2011","unstructured":"Dong H, Wang X, Dong Y et al (2011) Clinical pharmacokinetic\/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 38:296\u2013300","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"3740_CR19","doi-asserted-by":"publisher","first-page":"e00687","DOI":"10.1128\/AAC.00687-17","volume":"61","author":"A Galar","year":"2017","unstructured":"Galar A, Valerio M, Mu\u00f1oz P et al (2017) Systematic therapeutic drug monitoring for linezolid: variability and clinical impact. Antimicrob Agents Chemother 61(10):e00687-e717","journal-title":"Antimicrob Agents Chemother"},{"key":"3740_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/0091270010366445","volume":"51","author":"K Gandelman","year":"2011","unstructured":"Gandelman K, Zhu T, Fahmi OA et al (2011) Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 51:229\u2013236","journal-title":"J Clin Pharmacol"},{"key":"3740_CR21","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1128\/AAC.00757-10","volume":"54","author":"MS Bolhuis","year":"2010","unstructured":"Bolhuis MS, van Altena R, Uges DR et al (2010) Clarithromycin significantly increases linezolid serum concentrations. Antimicrob Agents Chemother 54:5418\u20135419","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"3740_CR22","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/jac\/dks153","volume":"67","author":"F Pea","year":"2012","unstructured":"Pea F, Viale P, Cojutti P et al (2012) Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 67(8):2034\u20132042","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"3740_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/FTD.0000000000000710","volume":"42","author":"GG Rao","year":"2020","unstructured":"Rao GG, Konicki R, Cattaneo D et al (2020) Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics. Ther Drug Monit 42(1):83\u201392","journal-title":"Ther Drug Monit"},{"issue":"5","key":"3740_CR24","doi-asserted-by":"publisher","first-page":"106783","DOI":"10.1016\/j.ijantimicag.2023.106783","volume":"61","author":"C Lau","year":"2023","unstructured":"Lau C, Marriott D, Bui J et al (2023) LInezolid Monitoring to MInimise Toxicity (LIMMIT1): a multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring. Int J Antimicrob Agents 61(5):106783","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"3740_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/jac\/dku337","volume":"70","author":"P Cojutti","year":"2015","unstructured":"Cojutti P, Maximova N, Crichiutti G et al (2015) Pharmacokinetic\/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. J Antimicrob Chemother 70(1):198\u2013206","journal-title":"J Antimicrob Chemother"},{"key":"3740_CR26","doi-asserted-by":"publisher","first-page":"967311","DOI":"10.3389\/fpubh.2022.967311","volume":"10","author":"B Lin","year":"2022","unstructured":"Lin B, Hu Y, Xu P et al (2022) Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front Public Health 10:967311","journal-title":"Front Public Health"},{"issue":"8","key":"3740_CR27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jsps.2019.09.002","volume":"27","author":"A Alsultan","year":"2019","unstructured":"Alsultan A (2019) Determining therapeutic trough ranges for linezolid. Saudi Pharm J 27(8):1061\u20131063","journal-title":"Saudi Pharm J"},{"key":"3740_CR28","unstructured":"FDA (2023) Linezolid prescribing information. U.S. Food and Drug Administration. Accessed 15 Jun 2023."},{"issue":"2","key":"3740_CR29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s11096-021-01342-y","volume":"44","author":"X Han","year":"2022","unstructured":"Han X, Wang J, Zan X et al (2022) Risk factors for linezolid-induced thrombocytopenia in adult inpatients. Int J Clin Pharm 44(2):330\u2013338","journal-title":"Int J Clin Pharm"},{"issue":"10","key":"3740_CR30","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3855\/jidc.10859","volume":"13","author":"E Kaya K\u0131l\u0131\u00e7","year":"2019","unstructured":"Kaya K\u0131l\u0131\u00e7 E, Bulut C, S\u00f6nmezer M\u00c7 et al (2019) Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination. J Infect Dev Ctries 13(10):886\u2013891","journal-title":"J Infect Dev Ctries"},{"issue":"2","key":"3740_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12519-022-00650-1","volume":"19","author":"Y Shi","year":"2023","unstructured":"Shi Y, Wu HL, Wu YH et al (2023) Safety and clinical efficacy of linezolid in children: a systematic review and meta-analysis. World J Pediatr 19(2):129\u2013138","journal-title":"World J Pediatr"},{"issue":"8","key":"3740_CR32","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.jiac.2021.03.003","volume":"27","author":"H Kato","year":"2021","unstructured":"Kato H, Hagihara M, Asai N et al (2021) A systematic review and meta-analysis of myelosuppression in pediatric patients treated with linezolid for Gram-positive bacterial infections. J Infect Chemother 27(8):1143\u20131150","journal-title":"J Infect Chemother"},{"issue":"12","key":"3740_CR33","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jiac.2019.05.025","volume":"25","author":"C Ogami","year":"2019","unstructured":"Ogami C, Tsuji Y, To H, Yamamoto Y (2019) Pharmacokinetics, toxicity and clinical efficacy of linezolid in Japanese pediatric patients. J Infect Chemother 25(12):979\u2013986","journal-title":"J Infect Chemother"},{"issue":"3","key":"3740_CR34","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/jpids\/piu035","volume":"4","author":"SJ Jones","year":"2015","unstructured":"Jones SJ, Nichols KR, DeYoung HL et al (2015) Linezolid-associated thrombocytopenia in children with renal impairment. J Pediatric Infect Dis Soc 4(3):272\u2013275","journal-title":"J Pediatric Infect Dis Soc"},{"key":"3740_CR35","doi-asserted-by":"publisher","first-page":"710099","DOI":"10.3389\/fphar.2022.710099","volume":"13","author":"L Duan","year":"2022","unstructured":"Duan L, Zhou Q, Feng ZA (2022) Regression model to predict linezolid induced thrombocytopenia in neonatal sepsis patients: a ten-year retrospective cohort study. Front Pharmacol 13:710099","journal-title":"Front Pharmacol"},{"issue":"6","key":"3740_CR36","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","volume":"41","author":"D Cattaneo","year":"2013","unstructured":"Cattaneo D, Orlando G, Cozzi V et al (2013) Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents 41(6):586\u2013589","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"3740_CR37","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1128\/AAC.00177-10","volume":"54","author":"F Pea","year":"2010","unstructured":"Pea F, Furlanut M, Cojutti P et al (2010) Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 54(11):4605\u20134610","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"3740_CR38","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2165\/00003088-200645100-00001","volume":"45","author":"ML Chen","year":"2006","unstructured":"Chen ML (2006) Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 45(10):957\u2013964","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3740_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40262-014-0209-3","volume":"54","author":"D Tsai","year":"2015","unstructured":"Tsai D, Jamal JA, Davis JS et al (2015) Interethnic differences in pharmacokinetics of antibacterials. Clin Pharmacokinet 54(3):243\u2013260","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3740_CR40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20(3):629\u2013637","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3740_CR41","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/jcph.1773","volume":"61","author":"SC Tang Girdwood","year":"2021","unstructured":"Tang Girdwood SC, Tang PH, Murphy ME et al (2021) Demonstrating feasibility of an opportunistic sampling approach for pharmacokinetic studies of \u03b2-lactam antibiotics in critically ill children. J Clin Pharmacol 61(4):565\u2013573","journal-title":"J Clin Pharmacol"},{"key":"3740_CR42","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s40262-015-0291-1","volume":"54","author":"S Leroux","year":"2015","unstructured":"Leroux S, Turner MA, Guellec CB et al (2015) Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design. Clin Pharmacokinet 54:1273\u20131285","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3740_CR43","first-page":"631","volume":"70","author":"A Cios","year":"2013","unstructured":"Cios A, Ku\u015b K, Szymura-Oleksiak J (2013) Determination of linezolid in human serum by reversed-phase high-performance liquid chromatography with ultraviolet and diode array detection. Acta Pol Pharm 70(4):631\u2013641","journal-title":"Acta Pol Pharm"},{"issue":"1","key":"3740_CR44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/INF.0000000000002067","volume":"38","author":"C Thibault","year":"2019","unstructured":"Thibault C, Kassir N, Goyer I et al (2019) Population pharmacokinetics of intravenous linezolid in premature infants. Pediatr Infect Dis J 38(1):82\u201388","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"3740_CR45","first-page":"e02504","volume":"95","author":"M Yang","year":"2023","unstructured":"Yang M, Zhao L, Wang X et al (2023) Population pharmacokinetics and dosage optimization of linezolid in critically ill pediatric patients. Antimicrob Agents Chemother 95(5):e02504\u2013e025020","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3740_CR46","doi-asserted-by":"publisher","first-page":"106881","DOI":"10.1016\/j.ijantimicag.2023.106881","volume":"62","author":"Lu Shi","year":"2023","unstructured":"Shi Lu, Zhang Y, Duan L et al (2023) Dose optimization of linezolid in critically ill patients based on a population pharmacokinetic model: a two-center prospective interventional study. Int J Antimicrob Agents 62(2):106881","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"3740_CR47","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/pharmaceutics14040753","volume":"14","author":"L Mockeliunas","year":"2022","unstructured":"Mockeliunas L, Keutzer L, Sturkenboom MGG et al (2022) Model-informed precision dosing of linezolid in patients with drug-resistant tuberculosis. Pharmaceutics 14(4):753","journal-title":"Pharmaceutics"},{"key":"3740_CR48","first-page":"420","volume":"1","author":"MDM Ballesteros Garc\u00eda","year":"2017","unstructured":"Ballesteros Garc\u00eda MDM, Or\u00f3s Mili\u00e1n ME, D\u00edaz Vel\u00e1zquez E et al (2017) Myelosupression induced by linezolid: a pediatric case. Arch Argent Pediatr 1:420\u2013423","journal-title":"Arch Argent Pediatr"},{"key":"3740_CR49","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/jcpt.12260","volume":"40","author":"T Ichie","year":"2015","unstructured":"Ichie T, Suzuki D, Yasui K et al (2015) The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis. J Clin Pharm Ther 40:279\u2013284","journal-title":"J Clin Pharm Ther"},{"key":"3740_CR50","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/bcpt.13123","volume":"124","author":"GW Choi","year":"2019","unstructured":"Choi GW, Lee JY, Chang MJ et al (2019) Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. Basic Clin Pharmacol Toxicol 124:228\u2013234","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"3740_CR51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3855\/jidc.18488","volume":"18","author":"L Thi Phuong Thao","year":"2024","unstructured":"Thi Phuong Thao L, Duc Trung N, Thi My L et al (2024) Association of clinical factors with thrombocytopenia in patients receiving linezolid treatment: a retrospective study. J Infect Dev Ctries 18(2):285\u2013290","journal-title":"J Infect Dev Ctries"},{"issue":"24","key":"3740_CR52","doi-asserted-by":"publisher","first-page":"e34059","DOI":"10.1097\/MD.0000000000034059","volume":"102","author":"S Yang","year":"2023","unstructured":"Yang S, Guo W, Chen M et al (2023) Prevalence and risk factors for severe linezolid-associated thrombocytopenia in pediatric patients: an analysis of a public database. Medicine (Baltimore) 102(24):e34059","journal-title":"Medicine (Baltimore)"},{"key":"3740_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.curtheres.2012.07.002","volume":"73","author":"C Chen","year":"2012","unstructured":"Chen C, Guo DH, Cao X et al (2012) Risk factors for thrombocytopenia in adult chinese patients receiving linezolid therapy. Curr Ther Res Clin Exp 73:195\u2013206","journal-title":"Curr Ther Res Clin Exp"},{"key":"3740_CR54","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1177\/08971900211048140","volume":"36","author":"S Kiliaki","year":"2023","unstructured":"Kiliaki S (2023) Piperacillin-tazobactam-induced immune thrombocytopenia: a case report. J Pharm Pract 36:451\u2013452","journal-title":"J Pharm Pract"},{"key":"3740_CR55","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1248\/bpb.b16-00427","volume":"39","author":"M Tajima","year":"2016","unstructured":"Tajima M, Kato Y, Matsumoto J et al (2016) Linezolid-induced thrombocytopenia is caused by suppression of platelet production via phosphorylation of myosin light chain 2. Biol Pharm Bull 39:1846\u20131851","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"3740_CR56","doi-asserted-by":"publisher","first-page":"dlaa114","DOI":"10.1093\/jacamr\/dlaa114","volume":"3","author":"NM Brown","year":"2021","unstructured":"Brown NM, Goodman AL, Horner C et al (2021) Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. JAC Antimicrob Resist 3(1):dlaa114","journal-title":"JAC Antimicrob Resist"},{"issue":"3","key":"3740_CR57","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE et al (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52(3):e18-55","journal-title":"Clin Infect Dis"},{"key":"3740_CR58","unstructured":"World Health Organization (2024) Global action plan on antimicrobial resistance. Available at: https:\/\/www.who.int\/antimicrobial-resistance\/publications\/global-action-plan\/en\/. Accessed 15 Apr 2024."}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03740-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03740-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03740-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T03:02:06Z","timestamp":1728270126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03740-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,25]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3740"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03740-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4526965\/v1","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,25]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted under the Declaration of Helsinki principles and was approved by the IRB at King Saud University Medical City (IRB approval number: E-22\u20136559).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No consent was required as our study was a non-interventional study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}